Calidi CFO granted 14,000 stock options at $1.36
Calidi Biotherapeutics, Inc. (CLDI) reported that its Chief Financial Officer, Jackson Andrew C., received a grant of 14,000 incentive stock options to purchase common stock.
Rhea-AI Filing Summary
Calidi Biotherapeutics, Inc. (CLDI) reported that its Chief Financial Officer, Jackson Andrew C., received a grant of 14,000 incentive stock options to purchase common stock. The options have an exercise price of $1.36 per share, equal to the closing price on August 17, 2026, and expire on August 17, 2036. Under the company’s 2023 Equity Incentive Plan, 25% of the options vest on the one-year anniversary of August 17, 2026, with the remaining 75% vesting in 36 equal monthly installments, subject to continued service. This grant does not include any incentive stock options previously awarded to the officer.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 14,000 shares
Grant/Award
1 txn
Insider
Jackson Andrew C.
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options (right to buy) F1, F2 | 14,000 | -- | -- |
Holdings After Transaction:
Stock Options (right to buy) — 14,000 contracts (Direct)
Footnotes (2)
- F1. Pursuant to the Issuer's 2023 Equity Incentive Plan (the "2023 Plan"), on August 17, 2026 (the "Grant Date"), the Reporting Person was granted 14,000 incentive stock options (the "Options") at an exercise price of $1.36, which is equal to the closing price of the Issuer's common stock on the Grant Date. 25% of the options will vest upon the one (1) year anniversary of 08/17/2026, and the remaining 75% of the options will vest in 1/36th installments on a monthly basis, subject to the Reporting Person's continued service to the Issuer. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person.
- F2. Does not include the incentive stock options previously granted to the Reporting Person.
Key Figures
Options Granted: 14,000 options
Exercise Price: $1.36 per share
Vesting Cliff Portion: 25%
+3 more
6 metrics
Options Granted
14,000 options
Incentive stock options granted to CFO on August 17, 2026
Exercise Price
$1.36 per share
Equal to closing price of common stock on August 17, 2026 grant date
Vesting Cliff Portion
25%
Vests on the one-year anniversary of August 17, 2026
Monthly Vesting Portion
75% over 36 months
Remaining options vest in 1/36th monthly installments after first year
Expiration Date
August 17, 2036
Option term under the 2023 Equity Incentive Plan
Derivative Holdings After Transaction
14,000 options
Total stock options from this grant held directly following the transaction
Key Terms
incentive stock options, 2023 Equity Incentive Plan, Rule 16b-3
3 terms
incentive stock options financial
"the Reporting Person was granted 14,000 incentive stock options (the "Options")"
Incentive stock options are a type of employee stock option that gives eligible workers the right to buy company shares at a fixed price later on, often below future market value. They matter to investors because they align employee incentives with company performance, can dilute existing ownership when exercised, and create potential tax advantages for option holders if certain holding-time rules are met — think of them as a coupon to buy stock at today’s price with extra tax rules attached.
2023 Equity Incentive Plan financial
"Pursuant to the Issuer's 2023 Equity Incentive Plan (the "2023 Plan")"
Rule 16b-3 regulatory
"The Options were granted in a transaction exempt under Rule 16b-3"
Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.
FAQ
What insider transaction did CLDI disclose for CFO Jackson Andrew C.?
Calidi Biotherapeutics (CLDI) disclosed that CFO Jackson Andrew C. was granted 14,000 incentive stock options. The options were issued under the 2023 Equity Incentive Plan with an exercise price of $1.36 per share and a 10-year term.
What is the exercise price and term of the new stock options granted by CLDI?
The new options carry an exercise price of $1.36 per share and expire on August 17, 2036. The exercise price equals the closing price of Calidi Biotherapeutics’ common stock on the August 17, 2026 grant date.
How do the CLDI stock options granted to the CFO vest over time?
The options vest 25% on the one-year anniversary of August 17, 2026, with the remaining 75% vesting in 1/36th monthly installments. Vesting is conditioned on the CFO’s continued service to Calidi Biotherapeutics.
Under which plan were the CLDI stock options for the CFO granted?
The options were granted under Calidi Biotherapeutics’ 2023 Equity Incentive Plan. The footnote specifies that the transaction is exempt under Rule 16b-3 and involves 14,000 incentive stock options at a $1.36 exercise price.
AI-generated analysis. How Rhea-AI works. Not financial advice.
